Drug Discovery & DDS– category –
-
AI Significantly Reduces Drug Discovery Space: De Novo Protein Design and Bruker’s Data Platform Accelerate Innovation
Temple 8 Unknown Overview AI models are drastically reducing the biological exploration space in drug discovery by screening billions of virtual molecules in seconds, predicting binding affinities, and optimizing pharmacokinetic properti... -
Exponential Progression of Targeted Protein Degradation: First FDA-Approved PROTAC and Molecular Glues Unlock “Undruggable” Targets
MarinBio (Appears to be a scientific review/journal, affiliated with MarinBio, hence using their domain) USA Overview The field of targeted protein degradation (TPD) is rapidly evolving, enabling the degradation of previously "undruggabl... -
AI-Designed Drugs from DeepMind’s AlphaFold, Insilico, and Generate Biomedicines Advance to Mid-Late Stage Clinical Trials, Intensifying Drug Discovery Race
MedCity News USA Overview The AI drug discovery sector is intensifying as advanced AI-designed drugs are poised to deliver mid-to-late stage clinical trial results within the next two years, leveraging breakthroughs like DeepMind's Alpha... -
Arvinas/Pfizer’s PROTAC Drug Veppanu Receives Historic FDA Approval for ESR1-Mutant Advanced Breast Cancer, Demonstrating 43% PFS Risk Reduction
Cancer Discovery - AACR Journals USA Overview Arvinas and Pfizer's oral PROTAC drug, Veppanu, has received FDA approval for advanced breast cancer with ESR1 mutations, marking the first clinical validation of targeted protein degradation... -
Engineered Antibody Brainshuttle™ Technology Boosts Brain Drug Delivery of RNA-Based ASOs by Dual-Targeting TfR1 and CD98hc Receptors, Illuminating CNS Disease Treatment
EMJ Unknown Overview Antibody-based Brainshuttle™ technology has made significant strides in brain drug delivery for promising therapeutics like RNA-based antisense oligonucleotides (ASOs), which are otherwise unable to cross the blood-b... -
Ionis Enters Global Licensing Deal with Recordati for Alexander Disease ASO Zilganersen: Secures $30M Upfront Payment to Accelerate International Expansion
Rare Disease Report USA Overview Ionis Pharmaceuticals has entered a global licensing agreement with Recordati for zilganersen, an antisense oligonucleotide (ASO) for Alexander disease, covering territories outside the U.S. Ionis will re... -
Asahi Kasei’s Novel Forward Osmosis–Membrane Distillation System Installed at Peptistar API Manufacturing Facility to Reduce Pharmaceutical Manufacturing Time for Thermolabile Peptides and Oligonucleotides, Advancing Towards GMP Production
Asahi Kasei Japan Overview Asahi Kasei has implemented a novel forward osmosis–membrane distillation (FO-MD) system at Peptistar's API manufacturing facility to shorten production times for thermolabile APIs like peptides and oligonucleo... -
Helus Pharma™’s Breakthrough-Designated Depression Drug HLP003 Completes 86% Enrollment in Phase 3 Trial, Topline Data Expected Q4 2026
PR Newswire Unknown Overview Helus Pharma™’s APPROACH Phase 3 trial for HLP003, an investigational adjunct therapy for major depressive disorder (MDD), has successfully completed over 86% of patient enrollment. HLP003 has received Breakt... -
ADC Therapeutics Completes Enrollment for LOTIS-7 Phase 1b Trial of Zynlonta-Glofitamab Combination, Reporting Interim 89.8% ORR in Relapsed/Refractory DLBCL Patients
BioPharm International Switzerland Overview ADC Therapeutics has completed patient enrollment for the Phase 1b LOTIS-7 trial, evaluating the combination of its CD19-targeted antibody-drug conjugate (ADC) Zynlonta with the bispecific anti... -
Focused Ultrasound BBB Opening Facilitates Limited LNP-modRNA Brain Delivery in Niemann-Pick Disease Type C Mouse Model but Fails to Induce Therapeutic Effect
bioRxiv Unknown Overview Efficient molecular therapeutic delivery to the central nervous system (CNS) remains a major barrier in neurogenetic disorders like Niemann-Pick Disease Type C (NPC). This preprint evaluated Focused ultrasound-me...
